Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-2.69%
1,068.24
-29.57
-2.69%
—1,097.811,087.761,087.761,067.42——
SIXC
Communications
SIXC
Communications
SIXC
-0.89%
606.59
-5.44
-0.89%
—612.03612.03612.03606.13——
SIXE
Energy
SIXE
Energy
SIXE
+2.19%
1,247.21
+26.78
+2.19%
—1,220.431,221.991,247.601,221.99——
SIXI
Industrials
SIXI
Industrials
SIXI
-1.82%
1,727.58
-31.94
-1.82%
—1,759.521,754.311,754.311,723.60——
SIXM
Financials
SIXM
Financials
SIXM
-0.32%
629.54
-2.00
-0.32%
—631.54631.27633.99628.63——
SIXR
Staples
SIXR
Staples
SIXR
-0.42%
853.60
-3.56
-0.42%
—857.16858.91861.71852.33——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-1.56%
212.04
-3.37
-1.56%
—215.41215.41215.41211.88——
SIXT
Technology
SIXT
Technology
SIXT
-1.78%
3,549.76
-64.39
-1.78%
—3,614.153,556.243,598.363,516.86——
SIXU
Utilities
SIXU
Utilities
SIXU
-2.40%
886.49
-21.81
-2.40%
—908.30906.55906.55885.88——
SIXV
Health care
SIXV
Health care
SIXV
-1.08%
1,464.34
-16.06
-1.08%
—1,480.401,479.551,484.431,462.52——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.84%
2,354.25
-44.12
-1.84%
—2,398.372,373.092,373.092,350.27——
IRWD:NASDAQ
Ironwood Pharmaceuticals, Inc.
$3.58
-2.45%
(-0.090) 1D
$3.55
-0.84% (-0.030)
After hours
Closed: May 15, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IRWD...
Open
$3.58
High
$3.59
Low
$3.47
Mkt. cap
589.32M
Avg. vol.
2.16M
Volume
2.18M
P/E ratio
6.12
52-wk high
$5.78
52-wk low
$0.53
EPS
$0.58
Beta
0.29
Shares outstanding
164.61M
No. of employees
100
News stories
From sources across the web
Profile
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. Wikipedia
About Ironwood Pharmaceuticals, Inc.
CEO-
Employees100
Founded1998
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websiteironwoodpharma.com
Last report
May 7, 2026
Fiscal Period
Q1 2026
EPS / Est. (USD)
$0.24 / $0.24
0.00%miss
Revenue / Est. (USD)
106.51M / 92.10M
+15.64%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
85.24M
122.06M
47.71M
106.51M
Cost of goods sold
23.37M
22.47M
21.86M
21.94M
Cost of revenue
23.37M
22.47M
21.86M
21.94M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.80M
21.91M
19.10M
12.03M
Operating expense
16.80M
21.91M
19.10M
12.03M
Total operating expenses
40.17M
44.38M
40.96M
33.97M
Operating income
45.07M
77.68M
6.75M
72.53M
Other non operating income
39.00K
40.00K
-116.00K
42.00K
EBT including unusual items
37.82M
68.02M
455.00K
65.17M
EBT excluding unusual items
37.57M
70.22M
203.00K
65.13M
Income tax expense
14.22M
27.94M
2.73M
24.40M
Effective tax rate
37.60%
41.08%
600.22%
37.44%
Other operating expenses
-
-
-
-
Net income
23.60M
40.08M
-2.28M
40.77M
Net profit margin
27.69%
32.84%
-4.77%
38.28%
Earnings per share
0.14
0.24
-0.01
0.24
Interest and investment income
818.00K
930.00K
1.46M
1.70M
Interest expense
-8.36M
-8.43M
-7.89M
-9.14M
Net interest expenses
-7.54M
-7.50M
-6.43M
-7.44M
Depreciation and amortization charges
-
-
-
-
EBITDA
45.54M
78.16M
7.21M
72.98M
Gain or loss from assets sale
85.00K
7.00K
-3.00K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer